You just read:

AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery

News provided by

AcelRx Pharmaceuticals, Inc.

Jan 21, 2016, 07:00 ET